vs

Side-by-side financial comparison of ANTERO RESOURCES Corp (AR) and Revvity (RVTY). Click either name above to swap in a different company.

ANTERO RESOURCES Corp is the larger business by last-quarter revenue ($1.4B vs $772.1M, roughly 1.8× Revvity). On growth, Revvity posted the faster year-over-year revenue change (5.9% vs -30.5%). ANTERO RESOURCES Corp produced more free cash flow last quarter ($235.6M vs $161.8M). Over the past eight quarters, ANTERO RESOURCES Corp's revenue compounded faster (17.6% CAGR vs 9.0%).

Antero Resources Corporation is an American company engaged in hydrocarbon exploration. It is organized in Delaware and headquartered in Denver, Colorado. The company's reserves are entirely in the Appalachian Basin and are extracted using hydraulic fracturing.

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

AR vs RVTY — Head-to-Head

Bigger by revenue
AR
AR
1.8× larger
AR
$1.4B
$772.1M
RVTY
Growing faster (revenue YoY)
RVTY
RVTY
+36.3% gap
RVTY
5.9%
-30.5%
AR
More free cash flow
AR
AR
$73.8M more FCF
AR
$235.6M
$161.8M
RVTY
Faster 2-yr revenue CAGR
AR
AR
Annualised
AR
17.6%
9.0%
RVTY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AR
AR
RVTY
RVTY
Revenue
$1.4B
$772.1M
Net Profit
$98.4M
Gross Margin
Operating Margin
20.1%
14.5%
Net Margin
12.7%
Revenue YoY
-30.5%
5.9%
Net Profit YoY
3.9%
EPS (diluted)
$0.66
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AR
AR
RVTY
RVTY
Q1 26
$1.4B
Q4 25
$1.4B
$772.1M
Q3 25
$1.2B
$698.9M
Q2 25
$1.3B
$720.3M
Q1 25
$1.4B
$664.8M
Q4 24
$1.2B
$729.4M
Q3 24
$1.1B
$684.0M
Q2 24
$978.7M
$691.7M
Net Profit
AR
AR
RVTY
RVTY
Q1 26
Q4 25
$202.9M
$98.4M
Q3 25
$85.6M
$46.7M
Q2 25
$166.6M
$53.9M
Q1 25
$219.5M
$42.2M
Q4 24
$158.8M
$94.6M
Q3 24
$-25.2M
$94.4M
Q2 24
$-74.6M
$55.4M
Gross Margin
AR
AR
RVTY
RVTY
Q1 26
Q4 25
Q3 25
53.6%
Q2 25
54.5%
Q1 25
56.5%
Q4 24
Q3 24
56.3%
Q2 24
55.7%
Operating Margin
AR
AR
RVTY
RVTY
Q1 26
20.1%
Q4 25
20.5%
14.5%
Q3 25
9.7%
11.7%
Q2 25
15.8%
12.6%
Q1 25
20.1%
10.9%
Q4 24
4.9%
16.3%
Q3 24
-2.4%
14.3%
Q2 24
-8.2%
12.4%
Net Margin
AR
AR
RVTY
RVTY
Q1 26
Q4 25
14.4%
12.7%
Q3 25
7.1%
6.7%
Q2 25
12.8%
7.5%
Q1 25
16.2%
6.4%
Q4 24
13.6%
13.0%
Q3 24
-2.4%
13.8%
Q2 24
-7.6%
8.0%
EPS (diluted)
AR
AR
RVTY
RVTY
Q1 26
$0.66
Q4 25
$0.63
$0.86
Q3 25
$0.24
$0.40
Q2 25
$0.50
$0.46
Q1 25
$0.66
$0.35
Q4 24
$0.48
$0.77
Q3 24
$-0.11
$0.77
Q2 24
$-0.26
$0.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AR
AR
RVTY
RVTY
Cash + ST InvestmentsLiquidity on hand
$919.9M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$7.6B
$7.3B
Total Assets
$13.2B
$12.2B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AR
AR
RVTY
RVTY
Q1 26
Q4 25
$919.9M
Q3 25
$931.4M
Q2 25
$991.8M
Q1 25
$1.1B
Q4 24
$1.2B
Q3 24
$1.2B
Q2 24
$2.0B
Total Debt
AR
AR
RVTY
RVTY
Q1 26
$1.4B
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
AR
AR
RVTY
RVTY
Q1 26
$7.6B
Q4 25
$7.6B
$7.3B
Q3 25
$7.3B
$7.4B
Q2 25
$7.3B
$7.6B
Q1 25
$7.2B
$7.6B
Q4 24
$7.0B
$7.7B
Q3 24
$7.0B
$7.9B
Q2 24
$7.0B
$7.9B
Total Assets
AR
AR
RVTY
RVTY
Q1 26
$13.2B
Q4 25
$13.2B
$12.2B
Q3 25
$12.9B
$12.1B
Q2 25
$12.8B
$12.4B
Q1 25
$13.0B
$12.4B
Q4 24
$13.0B
$12.4B
Q3 24
$13.2B
$12.8B
Q2 24
$13.4B
$13.4B
Debt / Equity
AR
AR
RVTY
RVTY
Q1 26
0.19×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AR
AR
RVTY
RVTY
Operating Cash FlowLast quarter
$457.7M
$182.0M
Free Cash FlowOCF − Capex
$235.6M
$161.8M
FCF MarginFCF / Revenue
17.4%
21.0%
Capex IntensityCapex / Revenue
2.6%
Cash ConversionOCF / Net Profit
1.85×
TTM Free Cash FlowTrailing 4 quarters
$509.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AR
AR
RVTY
RVTY
Q1 26
$457.7M
Q4 25
$370.7M
$182.0M
Q3 25
$310.1M
$138.5M
Q2 25
$492.4M
$134.3M
Q1 25
$457.7M
$128.2M
Q4 24
$278.0M
$174.2M
Q3 24
$166.2M
$147.9M
Q2 24
$143.5M
$158.6M
Free Cash Flow
AR
AR
RVTY
RVTY
Q1 26
$235.6M
Q4 25
$161.8M
Q3 25
$120.0M
Q2 25
$115.5M
Q1 25
$112.2M
Q4 24
$149.8M
Q3 24
$125.6M
Q2 24
$136.6M
FCF Margin
AR
AR
RVTY
RVTY
Q1 26
17.4%
Q4 25
21.0%
Q3 25
17.2%
Q2 25
16.0%
Q1 25
16.9%
Q4 24
20.5%
Q3 24
18.4%
Q2 24
19.7%
Capex Intensity
AR
AR
RVTY
RVTY
Q1 26
Q4 25
2.6%
Q3 25
2.6%
Q2 25
2.6%
Q1 25
2.4%
Q4 24
3.4%
Q3 24
3.3%
Q2 24
3.2%
Cash Conversion
AR
AR
RVTY
RVTY
Q1 26
Q4 25
1.83×
1.85×
Q3 25
3.62×
2.97×
Q2 25
2.96×
2.49×
Q1 25
2.09×
3.03×
Q4 24
1.75×
1.84×
Q3 24
1.57×
Q2 24
2.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AR
AR

Natural gas sales$780.0M58%
Natural gas liquids sales$561.4M42%
Oil sales$50.3M4%
Other revenue and income$818.0K0%

RVTY
RVTY

Immunodiagnostics$240.8M31%
Life Sciences$191.4M25%
Reproductive Health$149.3M19%
Segment Operating Income$132.0M17%
Software$62.3M8%

Related Comparisons